82 116

Cited 2 times in

Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury

DC FieldValueLanguage
dc.contributor.author이재훈-
dc.date.accessioned2019-05-29T05:27:29Z-
dc.date.available2019-05-29T05:27:29Z-
dc.date.issued2019-
dc.identifier.issn0041-1132-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/169607-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherAmerican Association Of Blood Banks-
dc.relation.isPartOfTRANSFUSION-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleTherapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Anesthesiology and Pain Medicine (마취통증의학교실)-
dc.contributor.googleauthorJae Hoon Lee-
dc.contributor.googleauthorJeonghyun Park-
dc.contributor.googleauthorJae-Woo Lee-
dc.identifier.doi10.1111/trf.14838-
dc.contributor.localIdA03092-
dc.relation.journalcodeJ02749-
dc.identifier.eissn1537-2995-
dc.identifier.pmid30383895-
dc.subject.keywordAcute respiratory distress syndrome is a major cause of respiratory failure in critically ill patients. Despite extensive research into its pathophysiology, mortality remains high. No effective pharmacotherapy exists. Based largely on numerous preclinical animal studies, administration of mesenchymal stem or stromal cell (MSC) as a therapeutic for acute lung injury (ALI) holds great promise, and Phase I and II clinical trials are currently under way internationally. However, concern for the use of stem cells, specifically the risk of iatrogenic tumor formation, as well as the prohibitive cost of production, storage, and distribution of cells in bone marrow transplant facilities, may limit access to this lifesaving therapy. Accumulating evidence now suggest that novel stem cell-derived therapies, including MSC-conditioned medium and extracellular vesicles (EVs) released from MSCs, might constitute compelling alternatives. The current review summarizes the preclinical studies testing MSC EVs as treatment for ALI and other inflammatory lung diseases. While certain logistic obstacles limit the clinical applications of MSC-conditioned medium such as the volume required for treatment and lack of standardization of what constitutes the components of conditioned medium, the therapeutic application of MSC EVs remains promising, primarily due to ability of EVs to maintain the functional phenotype of the parent cell. However, utilization of MSC EVs will require large-scale production and standardization concerning identification, characterization, and quantification.-
dc.contributor.alternativeNameLee, Jae Hoon-
dc.contributor.affiliatedAuthor이재훈-
dc.citation.volume59-
dc.citation.number1-
dc.citation.startPage876-
dc.citation.endPage883-
dc.identifier.bibliographicCitationTRANSFUSION, Vol.59(1) : 876-883, 2019-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Anesthesiology and Pain Medicine (마취통증의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.